This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kroeger, L. A.
Right arrow Articles by Rotschafer, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kroeger, L. A.
Right arrow Articles by Rotschafer, J. C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2007, p. 3431-3433, Vol. 51, No. 9
0066-4804/07/$08.00+0     doi:10.1128/AAC.01433-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Colistin Methanesulfonate against Multidrug-Resistant Acinetobacter baumannii in an In Vitro Pharmacodynamic Model{triangledown}

Lisa A. Kroeger, Laurie B. Hovde, Isaac F. Mitropoulos, Jeremy Schafer, and John C. Rotschafer*

The University of Minnesota College of Pharmacy, Antibiotic Pharmacodynamic Research Institute, Department of Experimental and Clinical Pharmacology, Minneapolis, Minnesota

Received 16 November 2006/ Returned for modification 7 March 2007/ Accepted 9 June 2007

Using an in vitro pharmacodynamic model, a multidrug-resistant strain of Acinetobacter baumannii was exposed to colistin methanesulfonate alone and in combination with ceftazidime. Pre- and postexposure colistin sulfate MICs were determined. A single daily dose of colistin methanesulfonate combined with continuous-infusion ceftazidime prevented regrowth and postexposure MIC increases.

* Corresponding author. Mailing address: Department of Experimental and Clinical Pharmacology, University of Minnesota College of Pharmacy, 9-157 Weaver-Densford Hall, 308 Harvard Street SE, Minneapolis, MN 55455. Phone: (612) 624-2183. Fax: (612) 626-5082. E-mail: rotsc001{at}umn.edu

{triangledown} Published ahead of print on 18 June 2007.

Antimicrobial Agents and Chemotherapy, September 2007, p. 3431-3433, Vol. 51, No. 9
0066-4804/07/$08.00+0     doi:10.1128/AAC.01433-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Moriyama, B., Henning, S. A, Neuhauser, M. M, Danner, R. L, Walsh, T. J (2009). Continuous-Infusion {beta}-Lactam Antibiotics During Continuous Venovenous Hemofiltration for the Treatment of Resistant Gram-Negative Bacteria. The Annals of Pharmacotherapy 43: 1324-1337 [Abstract] [Full Text]  
  • Landman, D., Georgescu, C., Martin, D. A., Quale, J. (2008). Polymyxins Revisited. Clin. Microbiol. Rev. 21: 449-465 [Abstract] [Full Text]  
  • Peleg, A. Y., Seifert, H., Paterson, D. L. (2008). Acinetobacter baumannii: Emergence of a Successful Pathogen. Clin. Microbiol. Rev. 21: 538-582 [Abstract] [Full Text]  
  • Zavascki, A. P., Goldani, L. Z., Li, J., Nation, R. L. (2007). Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother 60: 1206-1215 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»